Downward pressure on net sales is an ongoing problem for pharmaceutical and life sciences companies. It’s crucial to understand the gross-to-net (GNT) challenges that manufacturers are facing and how they can leverage their distribution strategies to optimize GTN. Understanding the challenges surrounding GTN Numerous factors impact a life science company’s GTN, which is the difference between the wholesaler acquisition cost (WAC) – also known as the drug’s list price – and the manufacturer’s net sales
Editor's Note: The consensus amongst healthcare industry experts is that the COVID-19 pandemic accelerated the shift to a more digital and consumer centric healthcare environment. With the shift underway and investment in healthcare technologies booming, many tout this as a silver lining of the pandemic. Despite this well found optimism, rapid technological change always unleashes unintended consequences
Though 2022 has been a down year for the biotechnology sector, notable decisions from the Food and Drug Administration have provided a few bright spots. Two gene therapies came to market, providing a lift for a field that’s been slowed by recent setbacks. The cancer drug Enhertu was approved for a newly defined tumor type known as “HER2-low.” The regulator also cleared a new medicine for ALS and a first-of-its-kind inflammatory disease drug
The seismic changes in consumer behavior and expectations brought on by mobile devices and cloud computing seem to have happened overnight, but they’ve been years in the making. The popularity of user-friendly services offered by the likes of Amazon, Uber, and Apple Pay has driven innovation and disruption across industries. The COVID-19 pandemic further accelerated the shift to digital tools, especially in healthcare
SAN FRANCISCO, Calif. – November 7, 2022 – Today, Phil Inc., a patient access platform company that revolutionizes life science product commercialization, announced its technology solution now offers expanded functionality for companies developing prescription digital therapeutics (PDTs). Using Phil’s platform, digital health companies can simplify the healthcare journey for patients with their prescription, manage both pharmacy and medical benefits processes and improve access to prescriptions
Ready to learn more?
Our consultants will work with you to analyze your current channel strategy and make recommendations for how to improve patient access and increase the percentage of scripts getting covered by insurance.